Danielle Ternyila

There was no difference in the occurrence of late toxicities between patients treated with radiotherapy alone or radiotherapy with short-term androgen deprivation therapy.

The FDA granted an Orphan Drug designation to zenocutuzumab for the treatment of patients with pancreatic cancer, announced Merus in a press release.

"We believe that poziotinib is a significant advancement for patients with this deadly disease in an area of high unmet medical need."

Second-line sunitinib demonstrated clinical activity after failure on frontline immunotherapy in patients with metastatic renal cell carcinoma.

“Given that the majority of the data analyzed in the study came from patients with relapsed/refractory disease, both autologous hematopoietic cell transplantation and allogeneic hematopoietic cell transplantation afford relatively high complete response rates when compared with established chemo-immunotherapy regimens and novel agents."

In an interview with Targeted Oncology, following the tweet chat, Shoushtari highlighted the key takeaways from the tweet chat discussion and spoke to how he would make his own treatment decisions for this patient scenario.

Ruxolitinib induced clinically meaningful reductions in both spleen size and symptoms for patients with myelofibrosis, including those with low platelet counts.

The Association of Community Cancer Centers (ACCC) has partnered with the American Society of Clinical Oncology (ASCO) in a collaborative effort to improve the participation of racial and ethnic minority populations in cancer clinical trials.

A 100% objective response rate was observed with CLR 131 as treatment of patients with relapsed/refractory lymphoplasmacytic lymphoma and Waldenström’s macroglobulinemia in the ongoing phase 2 CLOVER-1 study.

In an interview with Targeted Oncology, Delvys Rodriguez-Abreu, MD, discussed the findings from the KEYNOTE-189, which established the combination of pembrolizumab plus pemetrexed and platinum chemotherapy as the new standard of care for patients with metastatic nonsquamous non-small cell lung cancer.

The FDA cleared abivertinib to be investigated in a phase 2 clinical trial for the treatment of hospitalized patients with moderate to severe COVID-19.

In an interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the data from the MANIFEST trial, which evaluated the use of CPI-0610 as treatment of patients with myelofibrosis.

“Accurately identifying patients with high-grade UTUC is critical, as the disease progression can be deadly and the standard treatment – removal of ureter and kidney – leads to major morbidity."

The FDA has accepted the supplemental New Drug Application seeking approval of selinexor as treatment of patients with multiple myeloma following at least 1 prior line of therapy.

In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the current treatment landscape for acute myeloid leukemia and how he goes about sequencing the available agents when he treats patients in clinic.

Targeted Oncology reviews trending news online for the week of July 17, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

“The rationale behind the use of duvelisib is that the drug may be able to calm the systemic inflammation that exacerbates COVID-19-associated pneumonia and acute respiratory distress syndrome."

In an interview with Targeted Oncology, Alfonso E. Bencomo-Alvarez, PhD, discussed his research surrounding disparities in leukemias within the Hispanic community, particularly among the Hispanic population living at the border of Texas, in El Paso, and Mexico.

In an interview with Targeted Oncology, A. Oliver Sartor, MD, discussed the findings for subsequent 177Lu-PSMA following Radium-223 as treatment of patients with metastatic castration-resistant prostate cancer, as well as the next steps for this research.

The FDA has granted an Orphan Drug designation to APG-2575 for the treatment of patients with Waldenström macroglobulinemia.

“In this single-arm, phase 2 study, the combination of ofatumumab with the hyper-CVAD regimen resulted in a high proportion of adult patients with Ph-negative CD20- positive B-cell acute lymphoblastic leukemia having durable remission and long-term survival…"

“We are pleased the committee recognised the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options."

In an interview with Targeted Oncology, Thomas Cluzeau, MD, PhD, discussed the findings from the phase 2 study of azacitidine plus APR-246 as treatment of patients with TP53-mutant myelodysplastics syndrome and acute myeloid leukemia. He also highlighted the next steps for this treatment regimen.

In a single-arm phase 2 clinical trial, pyrotinib had promising antitumor activity as treatment of patients with HER2-positive non–small cell lung cancer.

The independent Data Monitoring Committee recommended stopping the global phase 3 OPTIMA clinical trial evaluating the combination of ThermoDox with radiofrequency ablation in hepatocellular carcinoma or primary liver cancer.

In an interview with Targeted Oncology, Balazs Halmos, MD, MS, discussed the current treatment landscape of EGFR-mutant NSCLC and how this space is evolving based on recent clinical trials.

In an interview with Targeted Oncology, Petros Grivas, MD, PhD, discussed the findings from the phase 3 JAVELIN Bladder 100 study, which evaluated the addition of avelumab to best supportive care in patients with locally advanced, unresectable or metastatic urothelial cancer.

The phase 3 IMagyn500 clinical trial failed to meet its primary end point of progression-free survival with the addition of atezolizumab to bevacizumab plus paclitaxel and carboplatin chemotherapy in patients with newly diagnosed advanced ovarian cancer.

In an interview with Targeted Oncology, Macarena de la Fuente, MD, discussed the findings from a phase 1b/2 study of olutasidenib as treatment of patients with relapsed/refractory IDH1-mutated gliomas, either alone or in combination with azacitidine.

Targeted Oncology reviews trending news online for the week of July 10, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.